Inflammatory myopathies: Issues in diagnosis and management

Arthritis and Rheumatism

Volumn 10, Issue 3, 1997, Pages 200-207

  Olsen, Nancy J ^a   Park, Jane H ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

CELL INFILTRATION; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOLOGY; LABORATORY DIAGNOSIS; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; REVIEW; SERODIAGNOSIS;

EID: 84988267471     PISSN: 0004-3591     EISSN: 1529-0131     Source Type: Journal    
DOI: 10.1002/art.1790100308     Document Type: Review

References (46)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
3. Miller FW. Inflammatory myopathies: polymyositis, dermatomyositis, and related conditions. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. Baltimore: Williams and Wilkins; 1997. p. 1407-31.
4. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I. Quantitation of subsets according to diagnosis and site of accumulation and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193-208.
5. Mantegazza R, Andreetta F, Bernasconi P, Baggi F, Oksenberg JR, Simoncini O, et al. Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis: restricted Vα/β rearrangements may indicate antigen-driven selection. J Clin Invest 1993;91: 2880-6.
6. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74.
7. Park JH, Vansant JP, Kumar NG, Gibbs SJ, Curvin MS, Price RR, et al. Dermatomyositis: correlative MR imaging and P-31 MR spectroscopy for quantitative characterization of inflammatory disease. Radiology 1990; 177:473-9.
8. Park JH, Vital TL, Ryder NM, Hernanz-Schulman M, Partain CL, Price RR, et al. Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum 1994;37:736-46.
9. Fraser DD, Frank JA, Dalakas M, Miller FW, Hicks JE, Plotz P. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991;18: 1693-9.
10. Newman ED, Kurland RJ. P-31 magnetic resonance spectroscopy in polymyositis and dermatomyositis: altered energy utilization during exercise. Arthritis Rheum 1992;35:199-203.
11. O'Rourke KS, Blaivas M, Ike RW. Utility of needle muscle biopsy in a university rheumatology practice (abstract). Arthritis Rheum 1990;33 Suppl 5:R30.
12. Haddad MG, West RL, Treadwell EL, Fraser DD. Diagnosis of inflammatory myopathy by percutaneous needle biopsy with demonstration of the focal nature of myositis. Am J Clin Pathol 1994;101:661-4.
13. Plotz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW. Myositis: immunologic contributions to understanding cause, pathogenesis and therapy. Ann Intern Med 1995;122:715-24.
14. Park JH, Olsen NJ, King L Jr, Vital T, Buse R, Kari S, et al. Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis. Arthritis Rheum 1995;38: 68-77.
15. Hernandez RJ, Keim DR, Chenevert TL, Sullivan DB, Aisen AM. Fat-suppressed MR imaging of myositis. Radiology 1992;182:217-9.
16. Kari S, Olsen NJ, Park JH. Evaluation of muscle diseases using artificial neural network analysis of 31P MR spectroscopy data. Magn Reson Med 1995;34:664-72.
17. King LE, Park JH, Adams L, Vital T, Olsen N. Evaluation of muscles in patients with suspected amyopathic dermatomyositis by magnetic resonance imaging and P-31 spectroscopy. J Am Acad Dermatol 1994;30:137-8.
18. Schweitzer ME, Fort J. Cost-effectiveness of MR imaging in evaluating polymyositis. Am J Radiol 1995;1469-71.
19. Pachman LM, Crawford S, Morello F, Maduzia L, Caliendo J, Sufit R, et al. MRI directed muscle biopsy for assessment of juvenile dermatomyositis response to therapy; comparison of initial and follow-up biopsies using a histological rating scale evaluating disease severity/chronicity (abstract). Arthritis Rheum 1996;39 Suppl 9:S191.
20. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: a review of 32 cases. J Rheumatol 1992;19: 1385-9.
21. Hochberg MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum 1986; 15:168-78.
22. Worrall JG, Phongsathorn V, Hooper RJL, Paice EW. Racial variation in serum creatinine kinase unrelated to lean body mass. Br J Rheumatol 1990;29:371-3.
23. Kagen LJ, Aram S. Creatine kinase inhibitor in sera from patients with muscle disease. Arthritis Rheum 1987;30: 213-7.
24. Rider LG, Miller FW. Laboratory evaluation of the inflammatory myopathies. Clin Diagn Lab Immunol 1995; 2:1-9.
25. Summers RM, Choyke PL, White P, George S, Katona I, Lindsley C, et al. Exercise increases STIR MRI signal intensity in juvenile dermatomyositis (abstract). Arthritis Rheum 1996;39 Suppl 9:S309.
26. Manfredi TG, Fielding RA, O'Reilly KP, Meredith CN, Lee HY, Evans WJ. Plasma creatine kinase activity and exercise-induced muscle damage in older men. Med Sci Sports Exerc 1991;23:1028-34.
27. Clarke AE, Bloch DA, Medsger TA Jr, Oddis CV. A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum 1995;38:1218-24.
28. Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986; 17:704-21.
29. Wortmann RL. Metabolic diseases of muscle. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. Baltimore: Williams & Wilkins; 1997. p. 2169-87.
30. Newman RJ, Bose P, Chan L, Gadian DJ, Styles P, Taylor D, et al. Nuclear magnetic resonance studies of forearm muscle in Duchenne dystrophy. BMJ 1982;284:1072-4.
31. Younkin DP, Berman P, Sladky J, Chee C, Bank W, Chance B. P-31 NMR studies in Duchenne muscular dystrophy: age-related metabolic changes. Neurology 1987;37:165-9.
32. Barbiroli B, Funicello R, Iotti S. 31P NMR spectroscopy of skeletal muscle in Becker dystrophy and DMD/BMD carriers: altered rate of phosphate transport. J Neurol Sci 1992;109:188-95.
33. Ross BD, Radda GK, Gadian G, Rocker G, Esri M, Falconer-Smith J. Examination of a case of suspected McArdle's syndrome by P-31 nuclear magnetic resonance. N Engl J Med 1981;304:1338-42.
34. Argov Z, Bank WJ, Maris J, Leigh JS, Chance B. Muscle energy metabolism in human phosphofructokinase deficiency as recorded by P31 magnetic resonance spectroscopy. Ann Neurol 1987;22:46-51.
35. Duboc D, Jehenson P, TranDinh S, Marsac C, Syrota A, Fardeu M. Phosphorus NMR spectroscopy of muscle enzyme deficiencies involving glycogenolysis and glycolysis. Neurology 1987;37:663-71.
36. Argov Z, Bank WJ, Boden B, Ro YI, Chance B. Phosphorus magnetic resonance spectroscopy of partially blocked muscle glycolysis. Arch Neurol 1987;44:614-7.
37. Arnold DL, Taylor DJ, Radda GK. Investigation of human mitochondrial myopathies by phosphorus magnetic resonance spectroscopy. Ann Neurol 1985;18:189-96.
38. Argov Z, Bank WJ, Maris J, Peterson P, Chance B. Bioenergetic heterogeneity of human mitochondrial myopathies: phosphorus magnetic resonance spectroscopy study. Neurology 1987;37:257-62.
39. Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 on muscular dystrophies and neurogenic atrophies. Biochem Biophys Acta 1995; 1271:281-6.
40. Campos Y, Huertas R, Lorenzo G. Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 1993;16:150-3.
41. Villalba ML, Hicks JE, Thornton B, Burgess S, Sherman J, Adams E, et al. A combination of oral methotrexate and azathioprine is more effective than high dose intravenous MTX with leucovorin rescue in treatment-resistant myositis (abstract). Arthritis Rheum 1995;38 Suppl 9:S307.
42. Roifman CM, Schaffer FM, Wachsmuth SE, Murphy G, Gelfand EW. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 1987;258:513-6.
43. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Ortero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329:1993-2000.
44. Leff RL, Miller FW, Hicks J, Fraser DD, Plotz PH. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine (Baltimore) 1993;72: 225-35.
45. Pistoia V, Buoncompagni A, Scribanis R, Fasce L, Alpigiani G, Cordone G, et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis: results of a preliminary study. Clin Exp Rheumatol 1993;11:203-8.
46. De Wilde A, DiSpaltro FX, Geller A, Szer IS, Klainer AS, Bisaccia E. Extracorporeal photochemotherapy as adjunctive treatment in juvenile dermatomyositis: a case report. Arch Dermatol 1992;128:1656-7.